Molnupiravir

Molnupiravir is an antiviral drug that is currently under investigation for its potential use in the treatment of COVID-19. It was developed by the pharmaceutical companies Merck and Ridgeback Biotherapeutics.

History

Molnupiravir was initially developed for the treatment of influenza. It was discovered by scientists at Emory University and is based on the compound N4-hydroxycytidine. The drug works by introducing errors into the RNA of the virus, which prevents the virus from replicating.

Clinical Trials

In 2020, Molnupiravir entered Phase II clinical trials for the treatment of COVID-19. Preliminary results from these trials have shown that the drug may reduce the duration of infectiousness for individuals with COVID-19.

Mechanism of Action

Molnupiravir works by introducing errors into the RNA of the virus, which prevents the virus from replicating. This is achieved through the drug's active metabolite, EIDD-2801, which is incorporated into the virus's RNA.

Potential Side Effects

As with any drug, Molnupiravir may have potential side effects. These can include nausea, diarrhea, and headache. However, these side effects are generally mild and temporary.

See Also

• COVID-19 pandemic
• Antiviral drug
• Clinical trial
• RNA

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

Molnupiravir

• 
  Molnupiravir chemical structure
• 
  Molnupiravir metabolism
• 
  Molnupiravir GC bonding
• 
  Molnupiravir AU bonding
• 
  Molnupiravir synthesis